Studies are irrelevant at this point, when we have population level data of over a billion people across India and Africa, and the massive disparities between states/countries that utilized Ivermectin, and those that did not. The drug is safe enough to be used based on this data alone. https://www.thedesertreview.com/opinion/columnists/indias-iv... https://www.thedesertreview.com/news/national/indias-ivermec... https…
When one option has billions of revenue at stake, investors will pay for more/focused studies vs an option to reuse low-cost generics. Unfortunately, or fortunately, desperate humans have skipped trials of both vaccines and early treatments, so there is data on both.